Frunevetmab (Solensia): Feline Osteoarthritis Pain Support in Oncology
- Entry kind
- Generic drug
- Product family
- Anti-NGF monoclonal antibodies
Quick summary
frunevetmab is covered as feline monoclonal-antibody analgesic for osteoarthritis pain; not an antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
What it is
Feline monoclonal-antibody analgesic for osteoarthritis pain; not an antitumour treatment. Frunevetmab.
Active ingredients / formula
Frunevetmab.
Mechanism / rationale
Frunevetmab binds feline nerve growth factor and reduces NGF-mediated pain signalling. It does not treat a tumour.
How it is discussed in tumor care
Cats with cancer can simultaneously have osteoarthritis. A separate pain diagnosis matters because guarding, reduced jumping and poor appetite can arise from tumour pain, arthritis or treatment effects.
Potential role
Cats with cancer can simultaneously have osteoarthritis. A separate pain diagnosis matters because guarding, reduced jumping and poor appetite can arise from tumour pain, arthritis or treatment effects.
Typical use context
Veterinarian-administered subcutaneous injection under the current label
Evidence snapshot
FDA approved Solensia for control of osteoarthritis pain in cats using a weight-of-evidence assessment. AAHA includes it as a supportive pain option, not as a cancer therapy.
Safety notes
Current product information and adverse-event reporting should be reviewed by the veterinarian. Skin, gastrointestinal or other new signs after treatment need assessment, particularly in medically complex cats.
Interactions / cautions
Concurrent analgesics, kidney disease, mobility change and the oncology plan require review. No inference should be made that monoclonal-antibody analgesia is automatically safer for every cat.
Regulatory status
FDA-approved for feline osteoarthritis pain, not for tumour control or a labelled cancer-pain indication.
Regions, labels and market differences
United States label described here; verify the relevant regional product information elsewhere.
Monitoring plan
Document baseline mobility and pain behaviours, examination findings and concurrent analgesics. Track jumping, grooming, litter-box access, appetite and new adverse signs. The veterinary team decides whether the observed pain remains consistent with osteoarthritis or needs tumour reassessment.
Questions to ask your veterinarian
- Does the confirmed diagnosis and species match the evidence population?
- What is labelled, conditionally authorised or extra-label in this region?
- Which objective findings will define benefit, toxicity and a change in plan?
- What household handling, waste and urgent-contact instructions apply?